Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Morishima T, Krahl AC, Nasri M, Xu Y, Aghaallaei N, Findik B, Klimiankou M, Ritter M, Hartmann MD, Gloeckner CJ, Stefanczyk S, Lindner C, Oswald B, Bernhard R, Hähnel K, Hermanutz-Klein U, Ebinger M, Handgretinger R, Casadei N, Welte K, Andre M, Müller P, Bajoghli B, Skokowa J.

Blood. 2019 Oct 3;134(14):1159-1175. doi: 10.1182/blood.2019000095. Epub 2019 Jul 31.

PMID:
31366618
2.

CRISPR/Cas9 mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients.

Nasri M, Ritter M, Mir P, Dannenmann B, Aghaallaei N, Amend D, Makaryan V, Xu Y, Fletcher B, Bernhard R, Steiert I, Hahnel K, Berger J, Koch I, Sailer B, Hipp K, Zeidler C, Klimiankou M, Bajoghli B, Dale DC, Welte K, Skokowa J.

Haematologica. 2019 Jun 27. pii: haematol.2019.221804. doi: 10.3324/haematol.2019.221804. [Epub ahead of print]

3.

Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.

Klimiankou M, Uenalan M, Kandabarau S, Nustede R, Steiert I, Mellor-Heineke S, Zeidler C, Skokowa J, Welte K.

Front Immunol. 2019 Feb 28;10:116. doi: 10.3389/fimmu.2019.00116. eCollection 2019.

4.

Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

Nasri M, Mir P, Dannenmann B, Amend D, Skroblyn T, Xu Y, Schulze-Osthoff K, Klimiankou M, Welte K, Skokowa J.

Blood Adv. 2019 Jan 8;3(1):63-71. doi: 10.1182/bloodadvances.2017015511.

5.

Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation.

Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, Morishima T, Schulze-Osthoff K, Zeidler C, Kanz L, Lachmann N, Moritz T, Welte K, Skokowa J.

Exp Hematol. 2019 Mar;71:51-60. doi: 10.1016/j.exphem.2018.12.006. Epub 2019 Jan 4.

PMID:
30615903
6.

NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.

Pylaeva E, Harati MD, Spyra I, Bordbari S, Strachan S, Thakur BK, Höing B, Franklin C, Skokowa J, Welte K, Schadendorf D, Bankfalvi A, Brandau S, Lang S, Jablonska J.

Int J Cancer. 2019 Jan 1;144(1):136-149. doi: 10.1002/ijc.31808. Epub 2018 Oct 30.

PMID:
30121947
7.

Severe congenital neutropenias.

Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K.

Nat Rev Dis Primers. 2017 Jun 8;3:17032. doi: 10.1038/nrdp.2017.32. Review.

8.

GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling.

Koch C, Samareh B, Morishima T, Mir P, Kanz L, Zeidler C, Skokowa J, Welte K.

Ann Hematol. 2017 Mar;96(3):345-353. doi: 10.1007/s00277-016-2894-5. Epub 2016 Dec 14.

PMID:
27966038
9.

Thrombopoietin induces hematopoiesis from mouse ES cells via HIF-1α-dependent activation of a BMP4 autoregulatory loop.

Pramono A, Zahabi A, Morishima T, Lan D, Welte K, Skokowa J.

Ann N Y Acad Sci. 2016 Jul;1375(1):38-51. doi: 10.1111/nyas.13138.

PMID:
27447537
10.

Role of CSF3R mutations in the pathomechanism of congenital neutropenia and secondary acute myeloid leukemia.

Klimiankou M, Mellor-Heineke S, Zeidler C, Welte K, Skokowa J.

Ann N Y Acad Sci. 2016 Apr;1370(1):119-25. doi: 10.1111/nyas.13097.

PMID:
27270496
11.

Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML.

Klimiankou M, Mellor-Heineke S, Klimenkova O, Reinel E, Uenalan M, Kandabarau S, Skokowa J, Welte K, Zeidler C.

Blood. 2016 May 26;127(21):2638-41. doi: 10.1182/blood-2015-12-685784. Epub 2016 Mar 30. No abstract available.

PMID:
27030388
12.

ELANE mutant-specific activation of different UPR pathways in congenital neutropenia.

Nustede R, Klimiankou M, Klimenkova O, Kuznetsova I, Zeidler C, Welte K, Skokowa J.

Br J Haematol. 2016 Jan;172(2):219-27. doi: 10.1111/bjh.13823. Epub 2015 Nov 16.

PMID:
26567890
13.

GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function biallelic heterozygous CSF3R mutations.

Klimiankou M, Klimenkova O, Uenalan M, Zeidler A, Mellor-Heineke S, Kandabarau S, Skokowa J, Zeidler C, Welte K.

Blood. 2015 Oct 8;126(15):1865-7. doi: 10.1182/blood-2015-07-661264. Epub 2015 Aug 31. No abstract available.

PMID:
26324699
14.

Neutrophils: Between host defence, immune modulation, and tissue injury.

Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth H, Benarafa C, Roos D, Skokowa J, Hartl D.

PLoS Pathog. 2015 Mar 12;11(3):e1004651. doi: 10.1371/journal.ppat.1004651. eCollection 2015 Mar. Review.

15.

miR-155 is associated with the leukemogenic potential of the class IV granulocyte colony-stimulating factor receptor in CD34⁺ progenitor cells.

Zhang H, Goudeva L, Immenschuh S, Schambach A, Skokowa J, Eiz-Vesper B, Blasczyk R, Figueiredo C.

Mol Med. 2015 Apr 9;20:736-46. doi: 10.2119/molmed.2014.00146.

16.

Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies.

Lachmann N, Ackermann M, Frenzel E, Liebhaber S, Brennig S, Happle C, Hoffmann D, Klimenkova O, Lüttge D, Buchegger T, Kühnel MP, Schambach A, Janciauskiene S, Figueiredo C, Hansen G, Skokowa J, Moritz T.

Stem Cell Reports. 2015 Feb 10;4(2):282-96. doi: 10.1016/j.stemcr.2015.01.005.

17.

The diversity of mutations and clinical outcomes for ELANE-associated neutropenia.

Makaryan V, Zeidler C, Bolyard AA, Skokowa J, Rodger E, Kelley ML, Boxer LA, Bonilla MA, Newburger PE, Shimamura A, Zhu B, Rosenberg PS, Link DC, Welte K, Dale DC.

Curr Opin Hematol. 2015 Jan;22(1):3-11. doi: 10.1097/MOH.0000000000000105. Review.

18.

TCIRG1-associated congenital neutropenia.

Makaryan V, Rosenthal EA, Bolyard AA, Kelley ML, Below JE, Bamshad MJ, Bofferding KM, Smith JD, Buckingham K, Boxer LA, Skokowa J, Welte K, Nickerson DA, Jarvik GP, Dale DC; UW Center for Mendelian Genomics.

Hum Mutat. 2014 Jul;35(7):824-7. doi: 10.1002/humu.22563. Epub 2014 May 21.

19.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

PMID:
24523240
20.

Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.

Gupta K, Kuznetsova I, Klimenkova O, Klimiankou M, Meyer J, Moore MA, Zeidler C, Welte K, Skokowa J.

Blood. 2014 Apr 17;123(16):2550-61. doi: 10.1182/blood-2012-09-456889. Epub 2014 Jan 6.

Supplemental Content

Loading ...
Support Center